TG Therapeutics, Inc. TGTX
57.43
(0.09)
(0.16%)
as of 25 Sep
- Market cap
- $8.8B
- P/E
- 18.9×
Follow TGTX
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
11.77 | 9.71 | 10.45 | 18.07 |
P/S ratio |
9.88 | 6.98 | 6.85 | 9.74 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 448.02 | |
P/Operating CF |
(226.92) | 218.82 | (268.15) | 198.38 | |
P/B ratio |
8.65 | 6.64 | 8.23 | 12.89 | |
Price to Tangible BV |
8.66 | 6.65 | 8.24 | 12.91 | |
EV/Sales |
10.09 | 7.15 | 7.18 | 9.99 | |
EV/EBITDA |
54.16 | 36.42 | 33.96 | 58.71 | |
EV/Operating CF |
(76.62) | (177.91) | (360.58) | 446.60 | |
EV/FCF |
(76.44) | (176.39) | (354.48) | 459.22 | |
Quick Ratio |
2.53 | 2.91 | 4.84 | 3.55 | |
Current Ratio |
3.82 | 4.10 | 5.81 | 4.27 | |
Net Debt/EBITDA |
3.93 | 2.05 | 6.63 | 8.87 | |
Debt/Assets |
23.94% | 23.10% | 48.74% | 45.46% | |
Debt/Equity |
0.40 | 0.38 | 1.28 | 1.23 | |
Asset Turnover |
0.66 | 0.75 | 0.64 | 0.68 | |
Operating CF/Net income |
(0.06) | 0.85 | (0.90) | 5.05 | |
Capex/Depreciation |
0.19 | 5.58 | 25.50 | (3.29) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
25.28% | 23.12% | 21.24% | 39.67% | |
Selling, General and Administrative Expense of Revenue |
39.19% | 30.85% | 45.43% | 34.17% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
10.94% | 8.13% | 9.74% | 11.60% | |
Graham Net Nets |
0.03 | 0.05 | 0.03 | 0.01 | |
Graham Number |
16.98 | 17.61 | 17.00 | 17.07 | |
Earnings Yield |
8.50% | 10.30% | 9.57% | 5.53% | |
Free Cash Flow Yield |
(1.34%) | (0.58%) | (0.30%) | 0.22% | |
Revenue per Share |
1.11 | 1.33 | 1.42 | 1.70 | |
Operating CF per Share |
(0.16) | 0.14 | (0.12) | 0.28 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.16) | 0.14 | (0.12) | 0.27 | |
Cash per Share |
0.90 | 0.98 | 3.56 | 3.90 | |
Shareholders Equity per Share |
4.18 | 4.49 | 4.04 | 4.26 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.18 | 4.49 | 4.04 | 4.26 | |
Free Cash Flow |
(23.23) | 19.59 | (17.94) | 38.97 | |
Working Capital |
442.96 | 477.00 | 899.86 | 877.19 | |
Capital Expenditures |
(0.08) | (0.07) | (0.05) | (0.29) | |
Net Current Asset Value |
181.96 | 215.53 | 141.26 | 110.14 | |
EV/EBIT |
52.24 | 35.74 | 33.65 | 58.56 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
241.73% | 11.96% | 9.65% | 3.24% | |
Price to Operating Income |
51.12 | 34.88 | 32.10 | 57.13 | |
| Other line items | |||||
Average Receivables |
190.56 | 217.41 | 291.08 | 316.54 | |
Average Payables |
106.87 | 82.90 | 141.39 | 173.86 | |
Average Inventory |
115.81 | 118.02 | 143.39 | 151.59 | |
Average Assets |
805.52 | 820.47 | 1,092.76 | 1,171.12 | |
Average Common Equity |
399.69 | 435.19 | 410.21 | 440.26 |
Columns are period end dates